The effects of a combination oral spray (Mucosamin®) for the prevention of oral mucositis in pediatric patients undergoing hematopoietic stem cell transplantation: a double blind randomized clinical trial

Shahrabi, Marzieh; Solduzian, Mohammad; Babaie, Molouk Hadji; Mousavi, S. Hossein; Goodarzi, Navid; Ravari, Nazanin Shabani; Sadeghi, Kourosh

doi:10.1007/s00520-022-07231-y

Cited by 4 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the influence of hyaluronic acid (HA) on cell signalling through its binding to CD44 is acknowledged [ 6 ], there is a notable absence of clinical studies thoroughly investigating the intricacies of the association between CD44 and HA and its consequential impact on chemotherapy treatment resistance across diverse tumor types. As recent studies have shown the clinical effectiveness of topical HA formulations in the reduction or prevention of mucositis in cancer patients undergoing chemotherapy [ 73 , 74 ], it is important to better understand the systemic and tumour-specific effect of the CD44–HA axis in clinical settings. Further research is imperative to elucidate this relationship from a clinical perspective before systemic HA medications can be safely used.…”

Section: Discussionmentioning

confidence: 99%

Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies

Wu,

Lu,

Loo

et al. 2024

IJMS

View full text Add to dashboard Cite

Cluster of differentiation 44 (CD44), a cell surface adhesion molecule overexpressed in cancer stem cells, has been implicated in chemoresistance. This scoping review, following PRISMA-ScR guidelines, systematically identified and evaluated clinical studies on the impact of CD44 expression on chemotherapy treatment outcomes across various cancer types. The search encompassed PubMed (1985–2023) and SCOPUS (1936–2023) databases, yielding a total of 12,659 articles, of which 40 met the inclusion criteria and were included in the qualitative synthesis using a predefined data extraction table. Data collected included the cancer type, sample size, interventions, control, treatment outcome, study type, expression of CD44 variants and isoforms, and effect of CD44 on chemotherapy outcome. Most of the studies demonstrated an association between increased CD44 expression and negative chemotherapeutic outcomes such as shorter overall survival, increased tumor recurrence, and resistance to chemotherapy, indicating a potential role of CD44 upregulation in chemoresistance in cancer patients. However, a subset of studies also reported non-significant relationships or conflicting results. In summary, this scoping review highlighted the breadth of the available literature investigating the clinical association between CD44 and chemotherapeutic outcomes. Further research is required to elucidate this relationship to aid clinicians in managing CD44-positive cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies

Wu,

Lu,

Loo

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…However, this raises the question as to whether CD44 engagement by HA triggers downstream pathways that culminate in the acquisition of a more aggressive phenotype. For example, HA-based nanocarriers have been developed to improve drug delivery efficiency and reduce off-target accumulation [28]; however, these HA-based compounds could trigger CD44 signalling pathways in cancer cells, leading to unintended consequences such as the promotion of tumor growth, invasion, or metastasis. In principle, these outcomes may occur if the nanoparticles interact with CD44 receptors in a manner that stimulates pro-tumorigenic signalling cascades or promotes cancer cell survival and proliferation.…”

Section: Introductionmentioning

confidence: 99%

The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer

Cirillo

2023

IJMS

View full text Add to dashboard Cite

Hyaluronic acid (HA) receptor CD44 is widely used for identifying cancer stem cells and its activation promotes stemness. Recent evidence shows that overexpression of CD44 is associated with poor prognosis in most human cancers and mediates therapy resistance. For these reasons, in recent years, CD44 has become a treatment target in precision oncology, often via HA-conjugated antineoplastic drugs. Importantly, HA molecules of different sizes have a dual effect and, therefore, may enhance or attenuate the CD44-mediated signaling pathways, as they compete with endogenous HA for binding to the receptors. The magnitude of these effects could be crucial for cancer progression, as well as for driving the inflammatory response in the tumor microenvironment. The increasingly common use of HA-conjugated drugs in oncology, as well as HA-based compounds as adjuvants in cancer treatment, adds further complexity to the understanding of the net effect of hyaluronan-CD44 activation in cancers. In this review, I focus on the significance of CD44 in malignancy and discuss the dichotomous function of the hyaluronan/CD44 axis in cancer progression.

show abstract

Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents

Gobbo,

Joy,

Guedes

et al. 2024

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

The effects of a combination oral spray (Mucosamin®) for the prevention of oral mucositis in pediatric patients undergoing hematopoietic stem cell transplantation: a double blind randomized clinical trial

Cited by 4 publications

References 40 publications

Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies

Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies

The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer

Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents

Contact Info

Product

Resources

About